Parasite Molecules as Immune Therapies: From Helminths to Autoimmune Treatments

Overview

This piece from Nature explores how parasitic worms have evolved molecules that suppress the host immune response and how scientists aim to repurpose these tricks as medicines for immune-related diseases. It also discusses the old friends hypothesis and the shift from infecting patients with live parasites to using parasite-derived molecules as drugs.

• Worm-derived molecules can calm immune responses in animal models of asthma, arthritis, rhinitis, colitis, sepsis and diabetes.
• The old friends hypothesis links reduced parasite exposure to rising autoimmune and allergic diseases.
• Early trials using live worm infections showed symptom improvements in some patients, but the approach is controversial; researchers now focus on parasite molecules as therapies.
• AI and modern technologies may speed up identifying effective worm-derived compounds and translating them into medicines.

Introduction

For millions of years, parasitic worms have evolved ways to survive inside hosts by dampening immune responses. Scientists are now studying these tricks with the aim of turning worm-derived molecules into medicines for autoimmune, inflammatory and allergic conditions. The concept rests on the idea that we might borrow nature’s solutions to control inflammation without introducing live parasites.

Worms and immune modulation

Helminths, including roundworms, tapeworms, hookworms and flukes, secrete a variety of molecules that can temper immune cell activity. Rather than directly attacking pathogens, these molecules influence immune signaling to allow worms to live and feed inside hosts for years. This has motivated researchers to isolate worm-derived molecules and modify them as potential drugs that recalibrate immune responses in humans.

From old friends to modern medicine

The old friends hypothesis proposes that our coevolution with internal parasites has shaped a balanced immune system. When parasite infections decline, rates of autoimmune, inflammatory and allergic diseases rise, prompting interest in deliberately exposing patients to live parasites or their eggs as a therapy. By the early 2000s, such ideas reached human clinical trials, including trials with Trichuris suis, the pig whipworm, which showed some symptom improvements in inflammatory bowel diseases. The approach proved controversial, leading researchers to pivot toward worm-derived molecules rather than live organisms as safer, more controllable therapies.

Evidence from animal models and human data

Recent work synthesizes hundreds of studies that document worm-derived molecules calming immune systems across asthma, arthritis, rhinitis, colitis, sepsis and diabetes in animal models. In parallel, experiments from the Galway group demonstrated that a molecule from the liver fluke could prevent multiple sclerosis in mice. These findings illustrate a potential to impact brain autoimmune conditions and inflammatory processes implicated in neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Are we there yet?

Translating worm biology into medicines will require careful navigation of biology differences between animals and humans. A drug that works in a mouse might fail in people, but advances in isolating worm molecules, clarifying their targets in humans and engineering them for therapeutic use offer real promise. Artificial intelligence could accelerate this search by screening large libraries of worm-derived molecules and predicting which are most likely to be effective and safe. Importantly, the goal is not to deploy parasites as drugs but to borrow their evolved strategies in purified, optimized forms.

Outlook

As researchers continue to identify parasite-derived molecules and adapt them for human therapy, there is cautious optimism that such biologically inspired approaches could provide new ways to control inflammation. The broader lesson is that some of nature’s oldest adversaries may harbor lessons for modern medicine, offering novel routes to treating diseases where immune regulation is defective.